These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9152571)

  • 1. The economic impact of the tacrine in the treatment of Alzheimer's disease.
    Henke CJ; Burchmore MJ
    Clin Ther; 1997; 19(2):330-45. PubMed ID: 9152571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential effect of tacrine on expenditures for Alzheimer's disease.
    Lubeck DP; Mazonson PD; Bowe T
    Med Interface; 1994 Oct; 7(10):130-8. PubMed ID: 10172130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic considerations in the treatment and management of Alzheimer's disease.
    Schumock GT
    Am J Health Syst Pharm; 1998 Nov; 55 Suppl 2():S17-21. PubMed ID: 9809107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.
    Migliaccio-Walle K; Getsios D; Caro JJ; Ishak KJ; O'Brien JA; Papadopoulos G;
    Clin Ther; 2003 Jun; 25(6):1806-25. PubMed ID: 12860500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tacrine and "profitability"].
    Nygaard HA
    Tidsskr Nor Laegeforen; 1997 Feb; 117(5):726. PubMed ID: 9102968
    [No Abstract]   [Full Text] [Related]  

  • 7. Tacrine for Alzheimer's disease. Costs and benefits.
    Knopman D
    Pharmacoeconomics; 1995 Apr; 7(4):275-9. PubMed ID: 10172459
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
    Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
    Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
    Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
    Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
    O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
    J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of survival analysis techniques in evaluating the effect of long-term tacrine (Cognex) treatment on nursing home placement and mortality in patients with Alzheimer's disease.
    Smith F; Talwalker S; Gracon S; Srirama M
    J Biopharm Stat; 1996 Nov; 6(4):395-409. PubMed ID: 8969976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
    Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy.
    Wallin AK; Gustafson L; Sjögren M; Wattmo C; Minthon L
    Dement Geriatr Cogn Disord; 2004; 18(2):197-206. PubMed ID: 15211076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
    McDonnell J; Redekop WK; van der Roer N; Goes E; Ruitenberg A; Busschbach JJ; Breteler MM; Rutten FF
    Pharmacoeconomics; 2001; 19(4):379-90. PubMed ID: 11383754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrine, and Alzheimer's treatments.
    Summers WK
    J Alzheimers Dis; 2006; 9(3 Suppl):439-45. PubMed ID: 16914883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.